| Symbol | BBNX |
|---|---|
| Name | BETA BIONICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 11 HUGHES,IRVINE, IRVINE, California, 92618, United States |
| Telephone | 949-427-7785 |
| Fax | — |
| — | |
| Website | https://www.betabionics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Beta Bionic is a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. Additional info from NASDAQ: |
Beta Bionics to Present at the Bank of America Securities Health Care Conference
Read more(48% Negative) BETA BIONICS, INC. (BBNX) Reports Q2 2026 Financial Results
Read moreBeta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Read moreNew Form ARS - Beta Bionics, Inc. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001193125-26-151334 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - Beta Bionics, Inc. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001193125-26-151291 <b>Size:</b> 266 KB
Read moreNew Form DEF 14A - Beta Bionics, Inc. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001193125-26-151235 <b>Size:</b> 1 MB
Read moreBeta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
Read moreBeta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
Read moreNew Form SCHEDULE 13G/A - Beta Bionics, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000724 <b>Size:</b> 7 KB
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Routine Care | OTHER | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Bionic Pancreas | DEVICE | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Dasiglucagon | DRUG | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| Insulin-only Bionic Pancreas | DEVICE | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| Bihormonal iLet Bionic Pancreas | DEVICE | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| iLet-based bionic pancreas | DEVICE | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| iPhone-based bionic pancreas | DEVICE | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| Glucagon | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| ZP4207 (dasiglucagon) | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| Insulin Lispro | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |